Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis

Examination of the Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis: A Randomized Controlled Single-Blind Trial

Multiple Sclerosis (MS) is a chronic, inflammatory, neurodegenerative, and autoimmune disease that progresses with progressive neurological dysfunction and affects the central nervous system. A multidisciplinary rehabilitation approach is crucial in the systematic and supportive treatment of MS. Exercise training is a therapeutic approach that minimizes functional capacity loss and slows progression in MS. Randomized controlled studies have shown that exercise training improves physical fitness, reduces motor fatigue, and improves the quality of life and psychological state in individuals with MS.

When the literature is examined, it is seen that popular exercises such as pilates, yoga, and Tai-Chi are used in addition to aerobics, strengthening, endurance, and stretching exercises in the treatment of individuals with MS. In order to eliminate the economic burden, which is one of the exercise barriers of individuals, and to gain exercise habits, home exercise programs should be expanded. When the literature is examined, it is emphasized that the importance of home exercise programs is emphasized, and it is very important in the treatment of patients who cannot attend an exercise program, especially by going to any center for various reasons. However, there is little information on the effectiveness and content of home exercise programs in patients with MS. From this point of view, this study is capable of supporting the missing part of the literature.

Study Overview

• Status: Completed
• Conditions: Multiple Sclerosis; Telerehabilitation; Autoimmune Disorder; Exercise Program
• Intervention / Treatment: Other: Fatigue Severity Scale; Other: Berg Balance Test; Other: Time up and go- 25 steps walking test; Other: Multiple Sclerosis Quality of Life; Other: Brief International Cognitive Assessment for MS (BICAMS); Other: Beck Depression and Anxiety Scale

• Study Type: Interventional
• Enrollment (Actual): 60
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Turkey
  • Merkez
    • Muğla, Merkez, Turkey, 48000
      • Muğla Sıtkı Koçman University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. To be between the ages of 18-65
2. Being diagnosed with MS according to McDonald criteria
3. Having an EDSS score between 0-5.5
4. Being in the Relapsing Remitting class as a clinical subtype of MS
5. Not having any nervous system pathology other than MS
6. Not having an MS attack in the last 1 month
7. To ensure full cooperation and adaptation throughout the study.

Exclusion Criteria:

1. Being in an exacerbation period
2. To have participated in a regular physical activity program in the last 6 months
3. Having an orthopedic, cardiopulmonary or psychiatric disease that prevents exercise
4. Continuing another exercise therapy
5. Not volunteering to participate in the study
6. Having problems with reading comprehension

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Control Group (CG); The control group will be queued to be included in the exercise program and participants' routine treatment will continue.	Other: Fatigue Severity Scale; Evaluation for severity of fatigue; Other: Berg Balance Test; Evaluation of balance; Other: Time up and go- 25 steps walking test; Evaluation for walking; Other: Multiple Sclerosis Quality of Life; Evaluation of quality of life; Other: Brief International Cognitive Assessment for MS (BICAMS); Evaluation of cognitive functions; Other: Beck Depression and Anxiety Scale; Evaluation of depression and anxiety
Experimental: Video Group (VG); The exercise will be given as a video and participants will be asked to continue the exercises for 8 weeks, 3 days a week. Patients will be contacted by phone every week to ask if participants have any problems with the exercise program and their compliance.	Other: Fatigue Severity Scale; Evaluation for severity of fatigue; Other: Berg Balance Test; Evaluation of balance; Other: Time up and go- 25 steps walking test; Evaluation for walking; Other: Multiple Sclerosis Quality of Life; Evaluation of quality of life; Other: Brief International Cognitive Assessment for MS (BICAMS); Evaluation of cognitive functions; Other: Beck Depression and Anxiety Scale; Evaluation of depression and anxiety
Experimental: Brochure Group (BG); Exercise will be given as a brochure and participants will be asked to continue the exercises given for 8 weeks, 3 days a week. Visual feedback will be provided by asking participants to mark the exercise tracking chart on the exercise brochures.	Other: Fatigue Severity Scale; Evaluation for severity of fatigue; Other: Berg Balance Test; Evaluation of balance; Other: Time up and go- 25 steps walking test; Evaluation for walking; Other: Multiple Sclerosis Quality of Life; Evaluation of quality of life; Other: Brief International Cognitive Assessment for MS (BICAMS); Evaluation of cognitive functions; Other: Beck Depression and Anxiety Scale; Evaluation of depression and anxiety

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Timed up and go with 25 steps walking test	Timed up and go: Patients wear their regular footwear and can use a walking aid, if needed.; The patient starts in a seated position; The patient stands up upon therapist's command: walks 3 meters, turns around, walks back to the chair and sits down.; The time stops when the patient is seated.; Be sure to document the assistive device used. Note: A practice trial should be completed before the timed trial. High falling risk>13.5 seconds. The 25 steps walking test is a quantitative mobility and leg function performance test based on a timed 25-walk. The patient is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is recorded.	Baseline- after 8 weeks (after treatment)
Fatigue Severity Scale	The Fatigue Severity Scale questionnaire contains nine statements that rate the severity of fatigue symptoms. A total score of less than 36 suggests that patient may not be suffering from fatigue. A higher score is indicated high level of fatigue.	Baseline- after 8 weeks (after treatment)
Brief International Cognitive Assessment for MS (BICAMS)	The Brief International Cognitive Assessment for MS (BICAMS) initiative was undertaken to recommend a brief, cognitive assessment for MS that is optimized for small centers. BICAMS was particularly focused on international use, to facilitate comparison across settings. An expert committee of twelve neurologists and neuropsychologists representing the main cultural groups that have so far contributed extensive data about cognitive dysfunction in MS was convened. The opinions generated from the meeting are published elsewhere. Consensus was also achieved on optimal measures for learning and memory in MS patients, time permitting: the initial learning trials of the second edition of the California Verbal Learning Test (CVLT2) and the revised Brief Visuospatial Memory Test (BVMTR).	Baseline- after 8 weeks (after treatment)
Berg Balance Scale	The Berg Balance Scale (BBS) is used to objectively determine a patient's ability (or inability) to safely balance during a series of predetermined tasks. It is a 14 item list with each item consisting of a five-point ordinal scale ranging from 0 to 4, with 0 indicating the lowest level of function and 4 the highest level of function and takes approximately 20 minutes to complete. A score of 56 indicates functional balance. A score of < 45 indicates individuals may be at greater risk of falling.	Baseline- after 8 weeks (after treatment)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Beck Depression and Anxiety Scale	The Beck Depression Scale is a 21-item self-reported questionnaire in which each item consists of four statements indicating different levels of severity of a particular symptom experienced over the past week. Scores for all 21 items are summed up to yield a single depression score. Scores of 0-12 are considered in the normal range, 13-18 as mild, 19-28 as moderate, and scores of 29-63 are considered to indicate severe depression. The Beck Anxiety Scale consists of 21 symptoms that are rated on a four-point severity scale referring to the experience of symptoms over the past week. Scores for the 21 items are summed up to yield a single anxiety score. Scores between 0 and 17 are considered as normal and mild anxiety, whereas scores over 25 are considered as severe anxiety.	Baseline- after 8 weeks (after treatment)
Mulitple Sclerosis Quality of life- 54	The MSQOL-54 is a multidimensional health-related quality of life measure that combines both generic and MS-specific items into a single instrument. The developers utilized the SF-36 as the generic component to which 18 items were added to tap MS-specific issues such as fatigue, cognitive function, etc. This 54-item instrument generates 12 subscales along with two summary scores, and two additional single-item measures. The subscales are: physical function, role limitations-physical, role limitations-emotional, pain, emotional well-being, energy, health perceptions, social function, cognitive function, health distress, overall quality of life, and sexual function. The summary scores are the physical health composite summary and the mental health composite summary. The single item measures are satisfaction with sexual function and change in health.	Baseline- after 8 weeks (after treatment)

Collaborators and Investigators

• Sponsor: Muğla Sıtkı Koçman University

Study record dates

Study Major Dates

• Study Start (Actual): September 30, 2021
• Primary Completion (Actual): November 30, 2021
• Study Completion (Actual): June 15, 2022

Study Registration Dates

• First Submitted: July 3, 2022
• First Submitted That Met QC Criteria: July 3, 2022
• First Posted (Actual): July 7, 2022

Study Record Updates

• Last Update Posted (Actual): July 20, 2022
• Last Update Submitted That Met QC Criteria: July 16, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Keywords: Exercise, Physical; Exercise Therapy; MS (Multiple Sclerosis); Physical Exertion
• Additional Relevant MeSH Terms: Pathologic Processes; Nervous System Diseases; Immune System Diseases; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Multiple Sclerosis; Sclerosis; Autoimmune Diseases
• Other Study ID Numbers: 200301

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No